Evaluation of Potential Antiplatelet Effects of CSL112, a Novel Formulation of Human Apolipoprotein A-I: Results From a Phase 2a Study
Publication
, Journal Article
Gurbel, PA; Bliden, KP; D'Andrea, DM; Henderson, KW; Alexander, JH; Tantry, US; Shear, C; Tricoci, P
Published in: CIRCULATION
November 26, 2013
Duke Scholars
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
November 26, 2013
Volume
128
Issue
22
Location
Dallas, TX
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gurbel, P. A., Bliden, K. P., D’Andrea, D. M., Henderson, K. W., Alexander, J. H., Tantry, U. S., … Tricoci, P. (2013). Evaluation of Potential Antiplatelet Effects of CSL112, a Novel Formulation of Human Apolipoprotein A-I: Results From a Phase 2a Study. CIRCULATION, 128(22).
Gurbel, Paul A., Kevin P. Bliden, Denise M. D’Andrea, Karen W. Henderson, John H. Alexander, Udaya S. Tantry, Charles Shear, and Pierluigi Tricoci. “Evaluation of Potential Antiplatelet Effects of CSL112, a Novel Formulation of Human Apolipoprotein A-I: Results From a Phase 2a Study.” CIRCULATION 128, no. 22 (November 26, 2013).
Gurbel PA, Bliden KP, D’Andrea DM, Henderson KW, Alexander JH, Tantry US, et al. Evaluation of Potential Antiplatelet Effects of CSL112, a Novel Formulation of Human Apolipoprotein A-I: Results From a Phase 2a Study. CIRCULATION. 2013 Nov 26;128(22).
Gurbel, Paul A., et al. “Evaluation of Potential Antiplatelet Effects of CSL112, a Novel Formulation of Human Apolipoprotein A-I: Results From a Phase 2a Study.” CIRCULATION, vol. 128, no. 22, LIPPINCOTT WILLIAMS & WILKINS, Nov. 2013.
Gurbel PA, Bliden KP, D’Andrea DM, Henderson KW, Alexander JH, Tantry US, Shear C, Tricoci P. Evaluation of Potential Antiplatelet Effects of CSL112, a Novel Formulation of Human Apolipoprotein A-I: Results From a Phase 2a Study. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2013 Nov 26;128(22).
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
November 26, 2013
Volume
128
Issue
22
Location
Dallas, TX
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology